Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Get Free Report)'s share price rose 7.8% during mid-day trading on Tuesday . The stock traded as high as $3.23 and last traded at $3.17. Approximately 431,762 shares were traded during mid-day trading, a decline of 47% from the average daily volume of 810,920 shares. The stock had previously closed at $2.94.
Analyst Ratings Changes
Separately, Cormark upgraded shares of Curaleaf from a "hold" rating to a "moderate buy" rating in a report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, According to MarketBeat.com, the company presently has an average rating of "Strong Buy".
Get Our Latest Stock Report on Curaleaf
Curaleaf Stock Up 8.7%
The company has a market cap of $2.14 billion, a PE ratio of -9.99 and a beta of 0.75. The company's 50 day moving average is $1.95 and its 200 day moving average is $1.27. The company has a current ratio of 1.47, a quick ratio of 0.70 and a debt-to-equity ratio of 1.00.
Curaleaf (OTCMKTS:CURLF - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.01. Curaleaf had a negative net margin of 18.08% and a negative return on equity of 14.61%. As a group, analysts predict that Curaleaf Holdings, Inc. will post -0.25 earnings per share for the current fiscal year.
Curaleaf Company Profile
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.